ClinicalTrials.gg
TerminatedNCT04658095Updated Oct 27, 2025Results posted

Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)

An interventional study of Canaloplasty and trabeculotomy with the OMNI system. and iStent inject in Glaucoma, Open-Angle, sponsored by Sight Sciences, Inc.. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Sight Sciences, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. — none open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Sight Sciences, Inc..

Started
2022
the only one that year
No phase
7 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc., this one is the only one that started in 2022, is one of 7 with no phase, and was the 5th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Glaucoma, Open-Angle by Sight Sciences, Inc. as a file.
02

Study summary

First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open angle glaucoma (OAG), and second, to compare safety and effectiveness outcomes for canaloplasty alone (using the OMNI Surgical System)to implantation of the iStent Inject in lowering IOP in pseudophakic eyes with OAG.

Read the detailed description

A multicenter, prospective, parallel group study planned to randomize 459 subjects to either 1)canaloplasty + trabeculotomy with the OMNI, 2)canaloplasty alone with the OMNI, or 3)iStent inject in an equal allocation ratio (1:1:1); The study includes baseline and terminal (Month 12) washout. Up to 26 centers in the UK and EU were planned to participate.

03

Conditions studied

  • Glaucoma, Open-Angle

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, 18 years or older
  2. Pseudophakic
  3. Diagnosis of open angle glaucoma (OAG)
  4. On 1-5 ocular hypotensive medications

Exclusion criteria

Exclusion Criteria:

  1. Any of the following prior treatments for glaucoma:

    • Suprachoroidal stent (e.g. Cypass, iStent Supra)
    • Laser trabeculoplasty ≤ 8 weeks prior to Baseline visit with a MIGS or other glaucoma device including but not limited to iStent, iStent inject, Hydrus, CyPass
    • Trabeculectomy or other bleb forming procedure including Xen, PreserFlo, Express, glaucoma draining device/valve
    • Prior canaloplasty, goniotomy, or trabeculotomy including procedures with GATT, Kahook Dual Blade, iTrack, Trabectome
    • Ciliary ablation procedures including Endocyclophotocoagulation (ECP), Cyclophotocoagulation (G probe), Micropulse laser, or high intensity focused ultrasound (HIFU)
  2. Any other form of glaucoma other than OAG
  3. Concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to investigator's office for follow-up visits).
  4. Women of if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate methods to prevent pregnancy throughout the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Ab-interno canaloplasty and trabeculotomy using the OMNI Surgical System

    Sequential canaloplasty (up to 360 degrees) and trabeculotomy (up to 360 degrees)

    Device: Canaloplasty and trabeculotomy with the OMNI system.

  • Active comparator
    Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System

    Canaloplasty alone (up to 360 degrees)

    Device: Canaloplasty

  • Active comparator
    Ab-interno implantation of iStent inject (2 microstents)

    Implantation of trabecular micro bypass stents as per manufacturer's instructions.

    Device: iStent inject

Interventions

  • DeviceCanaloplasty and trabeculotomy with the OMNI system.

    Ab-interno canaloplasty (360 degrees) and up to 360 degrees trabeculotomy

  • DeviceiStent inject

    Ab-interno implantation of iStent inject (2 microstents)

  • DeviceCanaloplasty

    Ab-interno canaloplasty (360 degrees) using the OMNI

06

What researchers measure

Primary outcomes

  1. Mean Change in Unmedicated DIOP From Baseline at the 12-month Postoperative Examination

    Mean change in unmedicated DIOP from baseline at the 12-month postoperative examination is the mean of the difference between the baseline DIOP and the Month 12 DIOP for each subject. Baseline and Month 12 DIOP are measured after appropriate washout of any glaucoma medications.

    Time frame: 12 months

07

Results

Posted Oct 27, 2025

Participant flow

Participant flow — Overall Study
MilestoneCanaloplasty Only With the OMNI Surgical SystemCanaloplasty + Trabeculotomy With the OMNI Surgical SystemiStent Inject
Started514
Completed000
Not completed514
Withdrew: Study terminated514

Outcome measures

PrimaryMean Change in Unmedicated DIOP From Baseline at the 12-month Postoperative Examination

Mean change in unmedicated DIOP from baseline at the 12-month postoperative examination is the mean of the difference between the baseline DIOP and the Month 12 DIOP for each subject. Baseline and Month 12 DIOP are measured after appropriate washout of any glaucoma medications.

Time frame:
12 months

No measurements were reported for this outcome.

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OMNI-canaloplasty Alone0/5 (0%)0/5 (0%)3/5 (60%)
OMNI-canaloplasty + Trabeculotomy0/1 (0%)0/1 (0%)1/1 (100%)
iStent Inject0/4 (0%)0/4 (0%)0/4 (0%)
Most frequent other events
Most frequent other events
EventOMNI-canaloplasty AloneOMNI-canaloplasty + TrabeculotomyiStent Inject
COVID-19 infectionRespiratory, thoracic and mediastinal disorders1/51/10/4
IOP elevationEye disorders2/50/10/4
Anterior chamber inflammationEye disorders1/50/10/4
Allergic conjunctivitisEye disorders1/50/10/4
TendinitisGeneral disorders1/50/10/4

Baseline characteristics

The safety analysis population will contain all subjects for whom either the OMNI (canaloplasty alone), OMNI (canaloplasty AND trabeculotomy), or iStent inject is attempted. The study was terminated early due to a business decision.

Age, Continuous
Age, Continuous(years)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
Mean75.6 ± 3.571 ± 074.5 ± 5.174.7 ± 4.0
Sex: Female, Male
Sex: Female, Male(Participants)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
Female2035
Male3115
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
Hispanic or Latino2013
Not Hispanic or Latino2136
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White5139
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
United Kingdom1012
Spain4127
Poland0011
Diurnal IOP (DIOP)
Diurnal IOP (DIOP)(mm Hg)OMNI-Canaloplasty OnlyOMNI-canaloplasty + TrabeculotomyiStent InjectTotal
Mean29.0 ± 4.426 ± 024.3 ± 0.526.8 ± 3.8
08

Study locations

5 sites
  • BurgerHospital
    Frankfurt, Germany
  • Institut Catala de Retina (ICR)
    Barcelona, 08022, Spain
  • Universidad Complutense de Madrid
    Valencia, 46026, Spain
  • Paseo Isabel la Católica 1-3. Edificio general Hospital Miguel Servet. Planta calle
    Zaragoza, 50009, Spain
  • Manchester Royal Eye Hospital
    Manchester, M13, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Nov 2022, 10 months.

Results were first posted in Oct 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2020
First posted
Dec 8, 2020
StartActual
Jan 11, 2022
Primary completionActual
Nov 18, 2022
CompletionActual
Nov 18, 2022
Results first posted
Oct 27, 2025
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04658095
Lead sponsor
Sight Sciences, Inc.
Responsible party
Sponsor
First posted
Dec 8, 2020
Start date
Jan 11, 2022
Primary completion
Nov 18, 2022
Completion
Nov 18, 2022
Results posted
Oct 27, 2025
Last update
Oct 27, 2025

Study contacts

Jaime Dickerson, PhD
study director · Sight Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion